Key result
Growth factor-pretreated MSCs increase regional wall thickening by ~11 percentage points over unmodified MSCs.
RCT (n=30)
2:1 randomization into two groups (n=20 vs n=10)
Answers are grounded in this paper and cite their sources.
The in vivo cardiac differentiation and functional effects of unmodified adult bone marrow mesenchymal stem cells (MSCs) after myocardial infarction (MI) is controversial. We postulated that ex vivo pretreatment of autologous MSCs using cardiomyogenic growth factors will lead to cardiomyogenic specification and will result in superior biological and functional effects on cardiac regeneration of chronically infarcted myocardium. We used a chronic dog MI model generated by ligation of the coronary artery (n = 30). Autologous dog bone marrow MSCs were isolated, culture expanded, and specified into a cardiac lineage by adding growth factors, including basic FGF, IGF-1, and bone morphogenetic protein-2. Dogs underwent cell injection >8 wk after the infarction and were randomized into two groups. Group A dogs (n = 20) received MSCs specified with growth factors (147 +/- 96 x 10(6)), and group B (n = 10) received unmodified MSCs (168 +/- 24 x 10(6)). After the growth factor treatment, MSCs stained positive for the early muscle and cardiac markers desmin, antimyocyte enhancer factor-2, and Nkx2-5. In group A dogs, prespecified MSCs colocalized with troponin I and cardiac myosin. At 12 wk, group A dogs showed a significantly larger increase in regional wall thickening of the infarcted territory (from 22 +/- 8 to 32 +/- 6% in group A; P < 0.05 vs. baseline and group B, and from 19 +/- 7 to 21 +/- 7% in group B, respectively) and a decrease in the wall motion score index (from 1.60 +/- 0.05 to 1.35 +/- 0.03 in group A; P < 0.05 vs. baseline and group B, and from 1.58 +/- 0.07 vs. 1.56 +/- 0.08 in group B, respectively). The biological ex vivo cardiomyogenic specification of adult MSCs before their transplantation is feasible and appears to improve their in vivo cardiac differentiation as well as the functional recovery in a dog model of the chronically infarcted myocardium.
No takes yet. Share an insight, caveat, or question.
Bartunek et al. (2006) conducted an RCT in Chronically infarcted myocardium (canine myocardial infarction model) (n=30). Autologous bone marrow mesenchymal stem cells (MSCs) pretreated ex vivo with cardiomyogenic growth factors (basic FGF, IGF-1, BMP-2) vs. Unmodified autologous MSCs (168 +/- 24 x 10^6 cells) was evaluated on Regional wall thickening of the infarcted territory at 12 weeks (p=<0.05). Growth factor-pretreated MSCs increased regional wall thickening and improved wall motion score index vs unmodified MSCs in chronic dog MI.
Synapse has enriched 10 related papers. Consider them for comparative context: